Food and Drug Administration Looks to Use Modelling and Simulation to Improve Clinical Trial Designs
Food and Drug Administration Looks to Use Modelling and Simulation to Improve Clinical Trial Designs
The Food and Drug Administration (FDA) is undertaking a new project to highlight how modelling and simulation can help with the development of medical devices and bring them to market in a more timely fashion. As part of this project, FDA is asking the public for assistance in identifying players in the bioengineering space familiar with Computation Human Heart Modeling Software and Services to conduct simulations and studies that can help move this project forward.
“Modeling and simulation can help to inform clinical trial designs, support evidence of effectiveness, identify the most relevant patients to study, and assess product safety. In some cases, in silico clinical trials have already been shown to produce similar results as human clinical trials,” Tina Morrison, deputy director of applied mechanics in the FDA’s Center for Devices and Radiological Health, said in a statement.
Through this new request for information (RFI) the FDA is seeking modelling and simulation software that can provide necessary information to develop and improve current medical devices used on the heart, such as pacemakers, without having to use more traditional trial methods. Acceptable modelling and simulation software should be capable of functions that include:
For further information and to submit a capability statement, click here: https://www.fbo.gov/index.php?s=opportunity&mode=form&id=fb56bc8127a061df7a37950ab185486d&tab=core&_cview=0
“Modeling and simulation can help to inform clinical trial designs, support evidence of effectiveness, identify the most relevant patients to study, and assess product safety. In some cases, in silico clinical trials have already been shown to produce similar results as human clinical trials,” Tina Morrison, deputy director of applied mechanics in the FDA’s Center for Devices and Radiological Health, said in a statement.
Through this new request for information (RFI) the FDA is seeking modelling and simulation software that can provide necessary information to develop and improve current medical devices used on the heart, such as pacemakers, without having to use more traditional trial methods. Acceptable modelling and simulation software should be capable of functions that include:
- Incorporates the three fundamental physics represented in the heart-electrical, structural, fluid;
- Spatially includes all four heart chambers as well as its peripheral vasculature
- Provides a computational human heart model that allows for electrophysiology and electromechanics of the heart
For further information and to submit a capability statement, click here: https://www.fbo.gov/index.php?s=opportunity&mode=form&id=fb56bc8127a061df7a37950ab185486d&tab=core&_cview=0
Related Content
5 Feedstocks for Biomass Energy Production
Apr 25, 2024
Wood, corn, even dung can heat homes and power industry. Discover energy from biomass.
Energy Blog: Noticeable Eclipse Impact on Electricity Sector
Apr 17, 2024
Breakthrough Could Make for Long-Range EVs
Apr 16, 2024
A simple method could lead to electric vehicles that can go much father on a single charge, and batteries that last years longer than present technology.
Using Lasers to Create the Power of the Stars on Earth
Apr 11, 2024
Doug Hammond and Focused Energy look to meet the challenges of developing laser-driven inertial confinement fusion energy for commercial electricity production.